102 related articles for article (PubMed ID: 26929887)
1. Long-term Remission Over Six Years for a Patient with Recurrent Glioblastoma Treated with Cediranib/Lomustine.
Drazin D; Al-Khouja L; Patel A; Hu J; Phuphanich S
Cureus; 2016 Jan; 8(1):e460. PubMed ID: 26929887
[TBL] [Abstract][Full Text] [Related]
2. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Batchelor TT; Mulholland P; Neyns B; Nabors LB; Campone M; Wick A; Mason W; Mikkelsen T; Phuphanich S; Ashby LS; Degroot J; Gattamaneni R; Cher L; Rosenthal M; Payer F; Jürgensmeier JM; Jain RK; Sorensen AG; Xu J; Liu Q; van den Bent M
J Clin Oncol; 2013 Sep; 31(26):3212-8. PubMed ID: 23940216
[TBL] [Abstract][Full Text] [Related]
3. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
Brandes AA; Gil-Gil M; Saran F; Carpentier AF; Nowak AK; Mason W; Zagonel V; Dubois F; Finocchiaro G; Fountzilas G; Cernea DM; Chinot O; Anghel R; Ghiringhelli F; Beauchesne P; Lombardi G; Franceschi E; Makrutzki M; Mpofu C; Urban HJ; Pichler J
Oncologist; 2019 Apr; 24(4):521-528. PubMed ID: 30266892
[TBL] [Abstract][Full Text] [Related]
5. NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma.
Batchelor TT; Won M; Chakravarti A; Hadjipanayis CG; Shi W; Ashby LS; Stieber VW; Robins HI; Gray HJ; Voloschin A; Fiveash JB; Robinson CG; Chamarthy U; Kwok Y; Cescon TP; Sharma AK; Chaudhary R; Polley MY; Mehta MP
Neurooncol Adv; 2023; 5(1):vdad116. PubMed ID: 38024244
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.
Weathers SP; Han X; Liu DD; Conrad CA; Gilbert MR; Loghin ME; O'Brien BJ; Penas-Prado M; Puduvalli VK; Tremont-Lukats I; Colen RR; Yung WKA; de Groot JF
J Neurooncol; 2016 Sep; 129(3):487-494. PubMed ID: 27406589
[TBL] [Abstract][Full Text] [Related]
7. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
Weller J; Tzaridis T; Mack F; Steinbach JP; Schlegel U; Hau P; Krex D; Grauer O; Goldbrunner R; Bähr O; Uhl M; Seidel C; Tabatabai G; Brehmer S; Bullinger L; Galldiks N; Schaub C; Kebir S; Stummer W; Simon M; Fimmers R; Coch C; Glas M; Herrlinger U; Schäfer N
Lancet Oncol; 2019 Oct; 20(10):1444-1453. PubMed ID: 31488360
[TBL] [Abstract][Full Text] [Related]
9. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme.
Gainer JL; Sheehan JP; Larner JM; Jones DR
J Neurosurg; 2017 Feb; 126(2):460-466. PubMed ID: 27177177
[TBL] [Abstract][Full Text] [Related]
10. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
Levin VA; Uhm JH; Jaeckle KA; Choucair A; Flynn PJ; Yung WKA ; Prados MD; Bruner JM; Chang SM; Kyritsis AP; Gleason MJ; Hess KR
Clin Cancer Res; 2000 Oct; 6(10):3878-84. PubMed ID: 11051233
[TBL] [Abstract][Full Text] [Related]
11. Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme.
Solero CL; Monfardini S; Brambilla C; Vaghi A; Valagussa P; Morello G; Bonadonna G
Cancer Clin Trials; 1979; 2(1):43-8. PubMed ID: 229983
[TBL] [Abstract][Full Text] [Related]
12. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
[TBL] [Abstract][Full Text] [Related]
13. Misonidazole and CCNU chemotherapy for recurrent primary brain tumor.
Fulton DS; Urtasun RC; McKinnon S; Tanasichuk H
J Neurooncol; 1987; 4(4):383-8. PubMed ID: 3033164
[TBL] [Abstract][Full Text] [Related]
14. Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine.
Stritzelberger J; Distel L; Buslei R; Fietkau R; Putz F
Clin Transl Oncol; 2018 Apr; 20(4):508-516. PubMed ID: 28825189
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
Gerstner ER; Ye X; Duda DG; Levine MA; Mikkelsen T; Kaley TJ; Olson JJ; Nabors BL; Ahluwalia MS; Wen PY; Jain RK; Batchelor TT; Grossman S
Neuro Oncol; 2015 Oct; 17(10):1386-92. PubMed ID: 26008604
[TBL] [Abstract][Full Text] [Related]
16. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
[TBL] [Abstract][Full Text] [Related]
17. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
Chamberlain MC; Tsao-Wei DD
Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma.
Duerinck J; Du Four S; Bouttens F; Andre C; Verschaeve V; Van Fraeyenhove F; Chaskis C; D'Haene N; Le Mercier M; Rogiers A; Michotte A; Salmon I; Neyns B
J Neurooncol; 2018 Jan; 136(1):115-125. PubMed ID: 28988341
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide.
Glas M; Happold C; Rieger J; Wiewrodt D; Bähr O; Steinbach JP; Wick W; Kortmann RD; Reifenberger G; Weller M; Herrlinger U
J Clin Oncol; 2009 Mar; 27(8):1257-61. PubMed ID: 19188676
[TBL] [Abstract][Full Text] [Related]
20. Lomustine and Bevacizumab in Progressive Glioblastoma.
Wick W; Gorlia T; Bendszus M; Taphoorn M; Sahm F; Harting I; Brandes AA; Taal W; Domont J; Idbaih A; Campone M; Clement PM; Stupp R; Fabbro M; Le Rhun E; Dubois F; Weller M; von Deimling A; Golfinopoulos V; Bromberg JC; Platten M; Klein M; van den Bent MJ
N Engl J Med; 2017 Nov; 377(20):1954-1963. PubMed ID: 29141164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
